Novo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LA

PR64693

BAGSVAERD, Denmark, June 6, 2016/PRNewswire=KYODO JBN/ --

    This material is intended for global medical media only.

    For journalistic assessment and preparation before publication.

    Novo Nordisk, a global leader in diabetes care, today announced that data

from 53 abstracts including 8 oral presentations will be shared at the upcoming

76th annual Scientific Sessions of the American Diabetes Association (ADA) in

New Orleans, LA, from 10-14 June.

    Following are key highlights that will be presented at the meeting:

    12 June, 8.30 am CDT, oral presentation

    - Phase 3a results from the SUSTAIN 2 clinical study comparing the efficacy

and safety of semaglutide with sitagliptin in people with type 2 diabetes

(#185-OR)

    12 June, 9.00 am CDT, oral presentation

    - Phase 3a results from the SUSTAIN 3 clinical study comparing the efficacy

and safety of semaglutide with exenatide extended release (ER) in people with

type 2 diabetes (#187-OR)

    12 June, 12.00 pm CDT, poster presentation

    - Phase 3b results from the SWITCH clinical studies comparing the

hypoglycaemia occurrence in people with type 1 diabetes on basal-bolus insulin

and type 2 diabetes on basal insulin treated with Tresiba(R) (insulin degludec

injection 100 Units/mL) vs insulin glargine U-100 in a blinded setting (#87-LB

and #90-LB)

    12 June, 3.00 pm CDT and 13 June, 8.45 am CDT, oral presentations

    - Phase 3a results from the onset clinical trials evaluating the efficacy of

faster-acting insulin aspart vs insulin aspart in people with type 1 and type 2

diabetes (#293-OR, #240-OR)

    12 June, 2.45 pm CDT, oral presentation

    - Results from DUAL V on IDegLira vs insulin glargine U-100 comparing

safety and efficacy in patients with uncontrolled type 2 diabetes (#239-OR)

    13 June, 2.15 pm CDT, oral presentation

    - Results from LEADER, a cardiovascular outcomes trial which investigated

the cardiovascular safety of Victoza(R) (liraglutide) injection in people with

type 2 diabetes at high risk of major adverse cardiovascular events

    11 June, 12.30 pm CDT, moderated poster discussion; 13 June, 12.00 pm CDT,

poster presentation

    - Data from the 2nd Diabetes Attitudes, Wishes and Needs (DAWN2) Study

relating to 'Concerns about Hypoglycemia' (#667-P)

    "ADA 2016 will be a landmark congress for Novo Nordisk. This year, we have

an unprecedented amount of key clinical data on our new insulins and GLP-1, and

we look forward to sharing it all with the medical and scientific community,"

said Mads Krogsgaard Thomsen, executive vice president and chief science

officer of Novo Nordisk. "The presented research demonstrates advances in

several areas of diabetes, underscoring our focus on developing innovative

treatments with the potential to improve the lives of people with diabetes."

    The above abstracts are a sampling of the data that will be presented or

published by Novo Nordisk. For a complete list of abstracts please click here:

www.abstractsonline.com/pp8/#!/4008 [http://www.abstractsonline.com/pp8/#!/4008

] .

    This press release contains forward-looking statements about

investigational products currently in development by Novo Nordisk. As is

expected, there is significant risk with drug development and there is no

guarantee that future studies will reflect similar results as presented at ADA.

For further information about the Novo Nordisk drug pipeline, visit

www.novonordisk.us [http://www.novonordisk.us ] .   

    About Novo Nordisk   

    Novo Nordisk is a global healthcare company with more than 90 years of

innovation and leadership in diabetes care. This heritage has given us

experience and capabilities that also enable us to help people defeat other

serious chronic conditions: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in

75 countries and markets its products in more than 180 countries. For more

information, visit novonordisk.com [http://www.novonordisk.com ], Facebook

[http://www.facebook.com/novonordisk ], Twitter

[http://www.twitter.com/novonordisk ], LinkedIn

[http://www.linkedin.com/company/novo-nordisk ], YouTube

[http://www.Youtube.com/novonordisk ].

    Further information  

    Media:

    Katrine Sperling

    +45-4442-6718

    krsp@novonordisk.com

    Asa Josefsson

    +45-3079-7708

    aajf@novonordisk.com

    Michael Bachner

    +1-609-664-7308

    mzyb@novonordisk.com

    Chris Clark

    +1-609-619-1831

    cpcr@novonordisk.com

    Investors:         

    Peter Hugreffe Ankersen

    +45-3075-9085

    phak@novonordisk.com

    Melanie Raouzeos

    +45-3075-3479

    mrz@novonordisk.com

    Kasper Veje (US)

    +1-609-235-8567

    kpvj@novonordisk.com

    SOURCE: Novo Nordisk